• Earlier this month, Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide) plus daratumumab and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy.
• This marks the first FDA-approved cereblon-modulating protein degrader and the first multiple myeloma approval based on minimal residual disease-negative complete response, highlighting a new regulatory path for BMS’s oncology portfolio.
• We’ll now examine how this first-in-class CELMoD approval based on MRD-negative complete response reshapes Bristol Myers Squibb’s broader investment narrative.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol Myers Squibb, you need to believe its next wave of oncology and immunology drugs can gradually replace revenue at risk from upcoming patent expirations. The ZENBEXUS accelerated approval strengthens the case that its CELMoD platform can contribute to that transition, but because it is conditional on confirmatory data and safety management, it does not materially change the near term risk that setbacks in key late stage programs could leave the company more exposed to its patent cliffs.

The ZENBEXUS news ties directly into Bristol Myers Squibb’s broader oncology push and recent investments in innovation, such as the new US$2.3 billion, multi modal manufacturing campus in Houston. That facility is designed to support a wide range of modalities, including complex oncology products, and helps frame iberdomide’s approval as part of a larger effort to sustain the portfolio beyond current blockbusters, even as pricing pressure and loss of exclusivity remain central concerns.

Yet while ZENBEXUS offers a fresh proof point for the pipeline, investors should also be aware that...

Bristol-Myers Squibb’s narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This implies a 6.2% yearly revenue decline but an earnings increase of about $1.3 billion from $7.3 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 6% downside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already expecting Bristol Myers Squibb’s revenue to fall to about US$36.8 billion and earnings to drop to roughly US$4.7 billion, so compared with the baseline view that focuses on pipeline offsets to patent risk, their narrative is much more pessimistic and ZENBEXUS could be one of the events that ultimately challenges or reinforces those assumptions over time.

Explore 6 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth as much as 77% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.